Medulloblastoma
113
17
31
42
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
26 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.0%
9 terminated out of 113 trials
82.4%
-4.2% vs benchmark
6%
7 trials in Phase 3/4
62%
26 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 42 completed trials
Clinical Trials (113)
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Rare CNS Tumors Outcomes &Risk
AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Targeting MYC in High-Risk Medulloblastoma
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Digoxin Medulloblastoma Study
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma
Methionine PET/CT Studies In Patients With Cancer
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma